 |
160 Products |  |
813 Diseases | | 160 Products |
|
1588 Trials |  |
77929 News |  |
| «12...889890891892893894895896897898899...903904» |
- Trial completion: Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=25, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Trial termination, Combination therapy, Metastases: QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors (clinicaltrials.gov) - Sep 30, 2012
P1/2, N=89, Terminated, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Sponsor decision - subjects rolled over to protocol 20101116
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change: Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 30, 2012
P2, N=0, Withdrawn, Sponsor: University of California, San Francisco
Active, not recruiting --> Terminated; Sponsor decision - subjects rolled over to protocol 20101116 N=36 --> 0
- |||||||||| rilotumumab (AMG 102) / Amgen
New P3 trial, Metastases: RILOMET-1: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (clinicaltrials.gov) - Sep 30, 2012
P3, N=450, Recruiting, Sponsor: Amgen
- ||||| abrilumab (AMG 181) / Amgen, AstraZeneca
New P2 trial: Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Sep 27, 2012
P2, N=252, Recruiting, Sponsor: Amgen
- Trial completion: Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes (clinicaltrials.gov) - Sep 27, 2012
P2, N=16, Completed, Sponsor: Case Comprehensive Cancer Center
N=36 --> 0 Active, not recruiting --> Completed
- ||| AMG 357 / Amgen
New P1 trial: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects (clinicaltrials.gov) - Sep 26, 2012
P1, N=58, Recruiting, Sponsor: Amgen
- ||||| abrilumab (AMG 181) / Amgen, AstraZeneca
New P2 trial: Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Sep 25, 2012
P2, N=360, Recruiting, Sponsor: Amgen
- Rituxan (rituximab) / Roche
Enrollment closed: Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer (clinicaltrials.gov) - Sep 25, 2012
P1/2, N=63, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Epogen (epoetin alfa) / Amgen
Enrollment change: Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa (clinicaltrials.gov) - Sep 24, 2012
P4, N=3, Terminated, Sponsor: University of South Florida
Recruiting --> Active, not recruiting N=20 --> 3
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P2 trial, Metastases: A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer (clinicaltrials.gov) - Sep 24, 2012
P2, N=44, Completed, Sponsor: University of Chicago
- Trial termination, Minimal residual disease: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=3, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=20 --> 3 Active, not recruiting --> Terminated; Low accrual
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: MAINTAIN: Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice (clinicaltrials.gov) - Sep 23, 2012
P4, N=780, Completed, Sponsor: Pfizer
- Neulasta (pegfilgrastim) / Roche
New P2 trial, Metastases: Dacarbazine and Carmustine in Metastatic Melanoma (clinicaltrials.gov) - Sep 23, 2012
P2, N=35, Recruiting, Sponsor: Western Regional Medical Center
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed: PALOMA-1;TRIO-18: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=177, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Terminated; Low accrual Recruiting --> Active, not recruiting
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=145, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion: Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer (clinicaltrials.gov) - Sep 23, 2012
P2, N=45, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Enrollment change: Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease (clinicaltrials.gov) - Sep 20, 2012
P3, N=358, Completed, Sponsor: Amgen
Active, not recruiting --> Completed N=540 --> 358
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Biomarker: Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=25, Recruiting, Sponsor: VU University Medical Center
- ||||||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial completion: Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease (clinicaltrials.gov) - Sep 20, 2012
P3, N=358, Completed, Sponsor: Amgen
N=540 --> 358 Recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
Trial termination: Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=47, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Completed Active, not recruiting --> Terminated; low accrual
- Stivarga (regorafenib) / Bayer
Stroma: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program) (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=0, Available, Sponsor: Bayer
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
New P3 trial: Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis (clinicaltrials.gov) - Sep 19, 2012
P3, N=240, Recruiting, Sponsor: Celgene Corporation
- | Trial completion: Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=222, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Sep 19, 2012
P3, N=214, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial initiation date: Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis (clinicaltrials.gov) - Sep 18, 2012
P4, N=200, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Initiation date: Jun 2010 --> Nov 2010
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Enrollment change: Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease (clinicaltrials.gov) - Sep 18, 2012
P4, N=20, Active, not recruiting, Sponsor: University of Maryland
Initiation date: Jun 2010 --> Nov 2010 N=40 --> 20
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients (clinicaltrials.gov) - Sep 18, 2012
P1, N=60, Completed, Sponsor: Amgen
- ||||||| Prolia (denosumab) / Amgen
Trial completion: A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates (clinicaltrials.gov) - Sep 18, 2012
P3, N=833, Completed, Sponsor: Amgen
N=40 --> 20 Active, not recruiting --> Completed
- ||||| Procysbi (cysteamine bitartrate delayed release) / Amgen
Enrollment change: Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) (clinicaltrials.gov) - Sep 16, 2012
P3, N=60, Active, not recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Active, not recruiting --> Completed N=30 --> 60
- | Procysbi (cysteamine bitartrate delayed release) / Amgen
Enrollment change: Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon (clinicaltrials.gov) - Sep 16, 2012
P3, N=43, Completed, Sponsor: Raptor Pharmaceuticals Inc.
N=30 --> 60 N=20 --> 43
- ||||| Procysbi (cysteamine bitartrate delayed release) / Amgen
Enrollment closed: Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) (clinicaltrials.gov) - Sep 16, 2012
P3, N=60, Active, not recruiting, Sponsor: Raptor Pharmaceuticals Inc.
N=20 --> 43 Recruiting --> Active, not recruiting
- || Procysbi (cysteamine bitartrate delayed release) / Amgen
Trial completion: Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon (clinicaltrials.gov) - Sep 16, 2012
P3, N=43, Completed, Sponsor: Raptor Pharmaceuticals Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| motesanib (AMG 706) / Takeda
Trial completion, Metastases: A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) - Sep 16, 2012
P2, N=184, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Herceptin (trastuzumab) / Roche
Trial completion: Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial (clinicaltrials.gov) - Sep 12, 2012
P1/2, N=40, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | motesanib (AMG 706) / Takeda
Trial termination, Combination therapy, Metastases: A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer (clinicaltrials.gov) - Sep 11, 2012
P2, N=282, Terminated, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Sponsor decision to close study
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 11, 2012
P=N/A, N=8, Terminated, Sponsor: University of California, San Francisco
Active, not recruiting --> Terminated; Sponsor decision to close study Completed --> Terminated; lack of efficacy
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 11, 2012
P=N/A, N=8, Terminated, Sponsor: University of California, San Francisco
Completed --> Terminated; lack of efficacy N=10 --> 8
- | motesanib (AMG 706) / Takeda
Trial completion, Combination therapy, Metastases: Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer (clinicaltrials.gov) - Sep 11, 2012
P1, N=46, Completed, Sponsor: Amgen
N=10 --> 8 Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia (clinicaltrials.gov) - Sep 10, 2012
P1, N=55, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed N=24 --> 55
- ||||| Ibrance (palbociclib) / Pfizer
New P1/2 trial: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Sep 10, 2012
P1/2, N=58, Active, not recruiting, Sponsor: Pfizer
- | prezalumab (AMG 557) / Amgen, AstraZeneca
New P1 trial: Safety Study of AMG 557 in Subjects With Lupus Arthritis (clinicaltrials.gov) - Sep 10, 2012
P1, N=40, Recruiting, Sponsor: Amgen
- buparlisib (AN2025) / Adlai Nortye, Vectibix (panitumumab) / Amgen
Enrollment open: P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. (clinicaltrials.gov) - Sep 10, 2012
P1/2, N=40, Recruiting, Sponsor: NCIC Clinical Trials Group
N=24 --> 55 Not yet recruiting --> Recruiting
- | Trial completion: Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia (clinicaltrials.gov) - Sep 10, 2012
P1, N=55, Completed, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Vectibix (panitumumab) / Amgen
Trial suspension: NEOREC-1: Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer (clinicaltrials.gov) - Sep 9, 2012
P2, N=48, Suspended, Sponsor: National Center for Tumor Diseases, Heidelberg
Active, not recruiting --> Completed Recruiting --> Suspended
- Neulasta (pegfilgrastim) / Roche, Rituxan (rituximab) / Roche
New P2 trial, Combination therapy: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma (clinicaltrials.gov) - Sep 6, 2012
P2, N=20, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
- | Rituxan (rituximab) / Roche
Enrollment change: CALGB-50303: Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 5, 2012
P3, N=523, Recruiting, Sponsor: Cancer and Leukemia Group B
Recruiting --> Suspended N=170 --> 523
- Rituxan (rituximab) / Roche
Enrollment closed: Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma (clinicaltrials.gov) - Sep 5, 2012
P2, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=170 --> 523 Recruiting --> Active, not recruiting
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) - Sep 5, 2012
P2, N=61, Active, not recruiting, Sponsor: Cancer and Leukemia Group B
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Vectibix (panitumumab) / Amgen
Enrollment closed: Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Sep 4, 2012
P2, N=64, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting